Scott R. Silverman, Chairman and CEO of PositiveID, said, We believe the benefits of the iGlucose system are obvious. It can provide improved health outcomes through real-time disease management, simplifying patients ™ lives and enhancing vital communication between patients and their healthcare providers. iGlucose also has the ability to decrease fraud and healthcare costs for providers and insurers by automatically creating compliant patient testing logs, which are required to comply with Medicare Part B reimbursement regulations.

A 2009 study, Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States, which was published in Value in Health, a leading pharmacoeconomics journal, and cited in the Company ™s white paper, found that in 2005, hospital charges alone and medical costs for individuals with diabetes exceeded $171 billion and $90 billion, respectively.

According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years.

SOURCE PositiveID Corporation